Physalin
B attenuates liver fibrosis via suppressing
LAP2 α-HDAC1 mediated
deacetylation of GLI1 and hepatic stellate cell activation
Running Title: Physalin B attenuates liver fibrosis via
suppressing deacetylation of GLI1
Xiaoyun Zhu, Shengtao Ye, Jie Li, Meihui Zhang, Yanqiu Zhang, Yingrong
Leng, Ting Yang, Jianguang Luo, Xinlin Chen, Hao Zhang*, Lingyi Kong*
State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of
Bioactive Natural Product Research, School of Traditional Chinese
Pharmacy, China Pharmaceutical University, Nanjing 210009, China
* Correspondence to:
Hao Zhang, State Key Laboratory of Natural Medicines and Jiangsu Key
Laboratory of Bioactive Natural Product Research, School of Traditional
Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang,
Nanjing 210009, China. E-mail:zhanghao@cpu.edu.cn ;
Lingyi Kong, State Key Laboratory of Natural Medicines and Jiangsu Key
Laboratory of Bioactive Natural Product Research, School of Traditional
Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang,
Nanjing 210009, China. E-mail:cpu_lykong@126.com;
Data availability: The data that support the findings of this
study are available from the corresponding author upon reasonable
request.
Funding: This work was supported by National Natural Science
Foundation of China (No. 82074068, 81872889) and Natural Science
Foundation of Jiangsu Province (BK20181332) to Hao Zhang. The Drug
Innovation Major Project (2018ZX09711-001-007 and 2018ZX09735002-003),
the “Double First-Class” University Project (CPU2018GF03) to Lingyi
Kong.
Author contributions: HZ
and XYZ conceived the study and
participated in the overall design, supervision, and coordination of the
study. XYZ designed and performed most experiments. STY, JL, MHZ
participated in molecular and cellular biological experiments. YRL, TY,
YQZ participated in animal studies. HZ and XYZ wrote the manuscript. LYK
supervised the overall project. All authors read and approved the
manuscript.
Acknowledgments: We cordially wish to acknowledge the cellular
platform and the pathology center for the excellent technical support.
Conflicts of interest: The authors declare no conflicts of
interest.
Ethicsapproval: All mice received human care and animal experiments
were approved by the University Committee on Use and Care of Animals of
the China Pharmaceutical University (Nanjing, China).
(Approval
NO.2020-0701)